Share Name Share Symbol Market Type Share ISIN Share Description
Neutec Pharma LSE:NTP London Ordinary Share GB0031275315 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p - - - - - - - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Unknown - - - - 0.00

Neutec Pharma (NTP) Latest News

Real-Time news about Neutec Pharma (London Stock Exchange): 0 recent articles
More Neutec Pharma News
Neutec Pharma Takeover Rumours

Neutec Pharma (NTP) Share Charts

1 Year Neutec Pharma Chart

1 Year Neutec Pharma Chart

1 Month Neutec Pharma Chart

1 Month Neutec Pharma Chart

Intraday Neutec Pharma Chart

Intraday Neutec Pharma Chart

Neutec Pharma (NTP) Discussions and Chat

Neutec Pharma Forums and Chat

Date Time Title Posts
15/4/200716:49NeuTec: MRSA, Cancer, Candidiasis, up for "grabs"201
06/6/200610:37Neutec with Charts & News-
19/9/200519:39Neutec targets MRSA253
05/10/200420:09Neutec the only way is up...97

Add a New Thread

Neutec Pharma (NTP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Neutec Pharma trades in real-time

Neutec Pharma (NTP) Top Chat Posts

bjfanc: Management sold out at the right time, as this wouldn't have been good for the share price. Close Print 17/11/2006, 2006, 3.03 PM CET Novartis to provide additional clarification to EU regulators on data supporting approval of Mycograb® for serious fungal infections Committee for Medicinal Products for Human Use (CHMP) issues negative opinion on 2005 Mycograb submission by NeuTec, which was acquired by Novartis in mid-2006 CHMP concluded that Mycograb demonstrated efficacy; negative opinion linked to questions about manufacturing and potential implications for product quality and safety Novartis to provide clarification to EU regulators to support Mycograb approval as a novel treatment for critically ill patients Basel, November 17, 2006 - Novartis announced today that it plans to submit additional information to the Committee for Medicinal Products for Human Use (CHMP) in Europe to support the approval of Mycograb®, in development as a treatment for life-threatening fungal infections, after the CHMP issued a negative recommendation. This submission for European Union approval was made in 2005 by the UK biopharmaceuticals company NeuTec Pharma, which Novartis acquired in mid-2006 to expand its portfolio of compounds for hospital-acquired fungal and bacterial infections. The CHMP opinion was not linked to the efficacy of the compound. The Committee concluded that there was insufficient data relating to the manufacturing and characterization of the product to determine the safety of the compound. Novartis is committed to working with the CHMP to determine appropriate next steps. Mycograb is a complex biological product produced through microbial fermentation and is produced by third party manufacturers. Novartis is working closely with these manufacturers and the CHMP to provide further clarification and analyses and is confident of gaining regulatory approval. Mycograb had not been submitted for approval in any other country. Mycograb is a twice-daily intravenous genetically recombinant antibody fragment, or "grab," add-on treatment targeting heat shock protein 90 ("hsp90") developed for treatment of invasive candidiasis. This life-threatening fungal infection, which is due to the Candida species, has a high mortality rate. In clinical trials, the combination of Mycograb plus amphotericin B demonstrated clear superiority over amphotericin B monotherapy, considered the standard of care. Mycograb binds to the fungal hsp90, disabling the fungal defense mechanism and making fungi more susceptible to medicines such as amphotericin B. Mycograb has been granted Orphan Drug status in Europe and the US for use against invasive fungal infections, including invasive candidiasis.
conan the trader: Telegraph: Swiss offer may start bid war for NeuTec A bidding battle could break out for NeuTec Pharma, which specialises in developing medicines for infectious diseases, after Switzerland's Novartis offered £305m for the company. Investors were optimistic a rival offer could materialise. Shares in the Manchester-based company rose higher than Novartis's offer price of £10.50 a share, to £10.80. The likelihood that NeuTec will be taken over has dramatically boosted the value of the stake owned by the husband and wife team who founded it. Yesterday James Burnie and Ruth Matthews saw their 7pc stake rise to £22m. Their holding had already gained strongly in value on Tuesday when NeuTec said it had received an offer, prompting its shares to soar by 84pc to 925p. Mr Burnie and Ms Matthews spun the company out of the University of Manchester in 1997, floating it on Aim in 2002 for £1.50 a share. The two have eschewed the large salaries biotech executives sometimes pay themselves, each taking home £107,000 last year. Novartis's offer is a 109pc premium to NeuTec's share price on Monday. NeuTec has recommended the offer. Other bidders that could gatecrash the deal include Pfizer, Merck, Eli Lilly, or Gilead. The company is regarded as one of the most attractive takeover targets in the biotech sector because it has several drugs in late-stage trials. In addition, it has no licensing deals with bigger rivals that a buyer would have to unwind. NeuTec's most promising drug, Mycograb, is under review by European regulators with a view to it being marketed as a treatment for invasive candidiasis, a potentially fatal form of thrush. A second medicine, Aurograb, is in final tests to treat MRSA, the hospital "superbug". By Katherine Griffiths (Filed: 08/06/2006)
papalpower: Make my day !! Lovely :) Neutec Pharma plc 6 June 2006 For immediate release NeuTec Pharma plc ('NeuTec' or the 'Company') The Board of NeuTec notes the recent movement in the Company's share price. The Company is currently in discussions which may or may not lead to an offer being made for the whole of the issued and to be issued share capital of the Company. There can be no certainty that agreement will be reached and an offer made. A further announcement will be made as appropriate. In accordance with Rule 2.10 of the City Code on Takeovers and Mergers, NeuTec announces that it has in issue 29,058,636 ordinary shares of 25 pence each. The International Securities Identification Number ('ISIN') for NeuTec ordinary shares is GB0031275315. Enquiries: NeuTec Pharma plc Professor James Burnie, CEO Telephone: +44 (0)161 276 8827
bountyhunter: good to see the share price up thats the most important thing Ill read the results properly when I am back in the uk kanbanwa from Tokyo
triktrak: Games, thanks for posting that. It's good to see the share price make up some lost ground. Still confident that with the approval of Mycograb and the success of Aurograb in Phase 3 trials, the share price will go considerably higher.
games: ABN Amro Keeps Buy Rating On NeuTec Pharma Thursday, June 16, 2005 11:40:05 AM ET Dow Jones Newswires 1520 GMT [Dow Jones] ABN Amro reiterates buy on NeuTec Pharma (NTP.LN). Reckons NeuTec remains well placed for 2H 05. "We see the recent share price weakness (-28% since March highs) as a good buying opportunity." Remains confident that Mycograb will be approved this year. Trades +7.8% at 520p. (SMT
triktrak: I wonder how much further this will drift. We've hit a barren patch for news. Mycograb won't be launched for at least another six months and - during the same period - we're unlikely to hear much further news of the Aurograb Phase III trials. So few announcements on those two leading products can be expected, even though progress is no doubt being made behind closed doors. At some stage the share price has to stabilise. The RSI-14 is now so low that it's almost disappeared off the chart, suggesting the stock has been very oversold. And, as far as I know, ABN maintains its fair value price of 950p a share. One can only hope that we're now near the bottom of the trough and that, given another few months, the fizz will be reinjected and the share price will ascend again. We all know that when NTP starts to motor, it's a sight to behold.
ramnik007: Cat / Bountyhunter - I was hoping the bullish investors like yourselves on this thread would point out reasons why the stock should be held (with facts and figures), however it appears the bullishness is just on risky speculation rather than good facts and figures. I bgt the shares based on share price momentum and assumed positive newsflow. When the price started to drift down I started some initial research in NTP, and had some questions which I thought the mgt could ansewr / clarify. However based on their refusal to even talk to me (at the time an investor),it appears they have no respect for private investors or have something to hide. I have sold my holding.
cat: From ABN'n note this am: Infection point In 2005, NeuTec needs to build on its impressive clinical data and move towards Mycograb commercialisation. Newsflow appears skewed to 2H05 and we expect positive regulatory progress, with Mycograb as the main focus. The stock remains our top pick. Key forecasts FY03A, FY04A, FY05F, FY06F, FY07F Revenue (£m) 0.00 0.00 0.00 7.03 37.9 EBITDA (£m) -3.39 -3.43 -9.44 -7.27 13.1 Reported PTP (£m) -2.94 -3.10 -8.36 -6.50 14.6 Normalised PTP (£m) -2.94 -3.10 -8.36 -6.50 14.6 Normalised EPS (p) -12.4 -13.1 -28.9 -22.5 50.5 Dividend per share (p) n/a n/a n/a n/a n/a Dividend yield (%) n/a n/a n/a n/a n/a Normalised PE (x) n/m n/m n/m n/m 9.77 EV/EBITDA (x) n/m n/m n/m n/m 8.42 EV/invested capital (x) n/m n/m n/m n/m n/m ROIC - WACC (%) 5242 272.1 778.7 714.8 -770.0 Source: Company data, ABN AMRO forecasts year to Jun, fully diluted Stunning Mycograb data in the bag NeuTec's lead drug, Mycograb (invasive candidiasis), has advanced rapidly with minimal financial outlay. Impressive pivotal data released in July 2004 resulted in a strong share price performance, but the current valuation still doesn't reflect the potential of this product, in our view. We expect EU regulatory filing in 1Q05 and EU approval in late 2005 to drive the shares. Aurograb phase III data still to come 2005 should see clinical progress with NeuTec's other key asset, Aurograb. Aurograb targets MRSA ("Hospital Superbug") infections, which are an increasingly high profile problem. We expect initial phase III data to be released in 2H05. Aurograb has the potential to be NeuTec's biggest selling product and early data, albeit from small clinical trials, was strikingly positive. Outlicensing deals - a potential "wildcard" Compelling Mycograb data puts NeuTec in a much stronger position in terms of licensing discussions with potential partners. The timing of any deal is difficult to forecast and we exclude any milestone payments from our forecasts and fair value. However, with pivotal data now in-hand, licensing deals may come quickly if the regulatory progress in Europe runs smoothly. We believe that a Japanese collaboration for Mycograb is the most likely candidate in the near term (2H05-2006). Valuation remains undemanding - lot of risk removed NeuTec remains our top pick in the UK sector. Although the more material newsflow remains skewed towards 2H05, we see incremental progress for NeuTec in early 2005. We believe regulatory progress in 2H05 should drive the share price towards our 950p fair value. Buy with an £8.00 price target. 0 Price £4.93 Target price £8.00 Market capitalisation £142.48m (.201.43m) Avg (12mth) daily volume £0.23m Monday 10 January 2005 * Buy Business overview NeuTec develops novel therapeutics for the treatment of life-threatening hospital acquired infections (HAIs). HAIs represent an increasingly high profile problem, accounting for 100,000 cases per year in the UK and causing around 5,000 deaths with a cost of around £1bn per year. Mycograb, NeuTec.s lead drug, is an antibody fragment for the treatment of invasive candidiasis, an acute, life-threatening fungal infection caused by Candida. Candida is one of the most common bloodstream infections responsible for around 70% of the 320,000 cases of systematic fungal infections reported globally each year. Pivotal phase II trial data was released in July 2004. Both primary and secondary endpoints were highly significant and Mycograb showed a mortality benefit, the first combination antifungal product to do so. Mycograb looks set to win solid market share and should command good terms from any partnership agreement. We forecast NeuTec will book peak revenues of £144m. Aurograb, NeuTec.s other key asset, targets Methicillin Resistant Staphylococcus aureus (MRSA), the so-called hospital superbug. In the UK, MRSA caused the death of 800 patients in 2002; a c15 fold increase in nine years. Aurograb entered Phase III trials in May 2004 and we expect initial data in 2H05. We expect Aurograb to sell £513m at peak, with NeuTec receiving a £64m royalty payment. Upside could come from NeuTec deciding to sell this product itself in Europe. Key issues Over the next 12-18 months NeuTec needs to transform from a pure play R&D biotech into a commercial operation. NeuTec took two major steps towards this goal in 2H04. ■ In October, Alan Cooke was appointed Head of Commercial Development. This was an important hire for NeuTec, in our view. Mr Cooke spent 10 years growing sales of the start up company Vestar, which after two mergers became Gilead. Importantly, his experience there included the launch of the first liposomal amphotericin-B (anti-fungal) in Europe, which overcame the previous .gold standard.. Here he took sales from zero to US$33m, winning 82% market share. ■ NeuTec signed a manufacturing agreement with CMC Biopharmaceuticals to provide commercial scale manufacturing capability. While exact deal terms were not disclosed, importantly management claims gross margins intact. Tight cost control has allowed NeuTec to reach this stage without the help of a partner. However, with the strong pivotal data in hand for Mycograb and a lack of interest in conducting an expensive Aurograb trial in the US, deals should be round the corner. Outlicensing deals would provide a cash injection (not included in our valuation model) and industry validation, which should drive the shares higher. Valuation Using a risk-adjusted NPV model for NeuTec, we derive a fair value of 954p. Our price target of 800p is based on our expectations for newsflow over the next six-to-12 months. Share price drivers include EU filing (expected 1Q05), potential EMEA approval (2H05), progress with Aurograb and the presentation of additional data on Mycograb at numerous scientific conferences. Downside risks to our target include regulatory delays and problems with manufacturing scale-up.
bountyhunter: Cat I agree entirely - it's one thing trying to prevent MRSA but all attempts to date have been pretty ineffective in the scheme of things with around 5000 deaths a year attributable to it. Before long Aurograb may become a life saver for many of those who are infected with MRSA despite the preventative measures which are being taken. If the phase III trials of Aurograb are successful the NTP share price could really fly; anyone know when these trials (which started in May 2004) are due to conclude?
Neutec Pharma share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180224 14:04:36